Sunday, February 17, 2013 8:16:25 PM
Odds are high they won't need any additional cash. They'd only need it if they intended to go to phase II or III and on to licensing. The CEO has indicated the likelihood of the company being sold after phase I.
This is a single event hold for me. I'm not looking long term here since I don't believe the company will exist in this form long term. They will most likely be bought out. Based on the following quote it is clear to me that the CEO is wanting to sell after phase I.
http://sunshinebiopharma.com/03-04-11-SunshineBiopharma11-CEOCFO-Article-Clean.pdf
CEOCFO: Are you looking to partner
or at what point would you perhaps go
from doing it on your own to adding
some other sources?
Dr. Slilaty: We imagine that at the
end of Phase I, once we publish the
results of human trials, we expect that
large pharmaceutical companies will
want to probably step in and buy it
from us at that point.
This is a single event hold for me. I'm not looking long term here since I don't believe the company will exist in this form long term. They will most likely be bought out. Based on the following quote it is clear to me that the CEO is wanting to sell after phase I.
http://sunshinebiopharma.com/03-04-11-SunshineBiopharma11-CEOCFO-Article-Clean.pdf
CEOCFO: Are you looking to partner
or at what point would you perhaps go
from doing it on your own to adding
some other sources?
Dr. Slilaty: We imagine that at the
end of Phase I, once we publish the
results of human trials, we expect that
large pharmaceutical companies will
want to probably step in and buy it
from us at that point.
Recent SBFM News
- Sunshine Biopharma Reports Fiscal 2025 Revenue of $36.3 Million, a 4.1% Increase Over Prior Year • ACCESS Newswire • 04/06/2026 12:30:00 PM
- Sunshine Biopharma Gains FDA-Equivalent Clearance in Canada for Domperidone to Treat Cancer-related Nausea • ACCESS Newswire • 10/28/2025 11:45:00 AM
- Sunshine Biopharma Launches STD, Acne and Lyme Disease Therapy Doxycycline • ACCESS Newswire • 10/20/2025 11:45:00 AM
- Sunshine Biopharma Launches Cholesterol Fighting Medicine Pravastatin • ACCESS Newswire • 10/16/2025 11:45:00 AM
- Sunshine Biopharma Allocates $5 Million for Investment in Bitcoin as Strategic Reserve Asset to Enhance Treasury Resilience • ACCESS Newswire • 10/14/2025 11:00:00 AM
- Sunshine Biopharma and University of Arizona Develop a Potent New Series of Protease Inhibitors for Treatment of SARS Coronavirus Infections • ACCESS Newswire • 10/09/2025 12:00:00 PM

